CureVac sees cash runway into 2028

Cash and cash equivalents totaled EUR 416.1 million as of September 30, 2025, compared with EUR 481.7 million at year-end 2024. During the first nine months of 2025, cash was mainly used for operating activities, primarily to support ongoing research and development in oncology precision immunotherapies, prophylactic vaccines, and continued development of CureVac’s (CVAC) mRNA technology. Cash outflow decreased significantly compared to the same period in 2024, mainly due to: Non recurrence of extraordinary payments in the prior year related to the termination of raw material commitments and contract manufacturing organization-related arbitration awards for the first-generation COVID-19 vaccine CVnCoV, and the strategic restructuring initiated in July 2024 reduced personnel expenses and introduced broader cost-saving measures across the organization. The company reaffirms its expected cash runway into 2028.